Zai Lab (ZLAB) Expected to Announce Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Zai Lab to post earnings of ($0.38) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Zai Lab Trading Up 0.7%

ZLAB stock opened at $20.18 on Thursday. The stock has a market cap of $2.28 billion, a P/E ratio of -10.35 and a beta of 0.88. Zai Lab has a twelve month low of $15.96 and a twelve month high of $44.34. The company’s 50 day moving average is $18.14 and its two-hundred day moving average is $25.06.

Insiders Place Their Bets

In other news, insider Rafael Amado sold 10,787 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $17.43, for a total value of $188,017.41. Following the transaction, the insider owned 52,391 shares of the company’s stock, valued at approximately $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.96% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on ZLAB. UBS Group began coverage on shares of Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. Zacks Research downgraded Zai Lab from a “hold” rating to a “strong sell” rating in a report on Friday, January 23rd. Jefferies Financial Group raised Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Finally, JPMorgan Chase & Co. cut their price target on Zai Lab from $46.00 to $39.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Zai Lab currently has an average rating of “Moderate Buy” and a consensus price target of $51.59.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.